| P2093 | author name string | Giuseppe Parisi | |
| | Emanuele Tumino | |
| | Giampaolo Bresci | |
| | Salvatore Metrangolo | |
| | Sara Marceglia | |
| | Rodolfo Sacco | |
| | Luca Giacomelli | |
| | Caterina Conte | |
| | Giuseppe Cabibbo | |
| | Roberto Eggenhoffner | |
| P2860 | cites work | Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 | Q21534928 |
| | Hepatocellular carcinoma: Where are we? | Q26765182 |
| | Transarterial chemoembolization using drug eluting beads for the treatment of hepatocellular carcinoma: Now and future | Q26771776 |
| | Recent Advances in Tumor Ablation for Hepatocellular Carcinoma | Q26775418 |
| | Sorafenib in advanced hepatocellular carcinoma | Q27861075 |
| | Hepatocellular carcinoma: epidemiology and molecular carcinogenesis | Q28306363 |
| | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial | Q29547903 |
| | Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013 | Q30358426 |
| | Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study | Q33691454 |
| | Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma | Q34089023 |
| | Hepatocellular Carcinoma: Consensus Recommendations of the National Cancer Institute Clinical Trials Planning Meeting | Q34131801 |
| | Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis | Q34585175 |
| | Gastrointestinal complications associated with hepatic arterial Yttrium-90 microsphere therapy. | Q34620919 |
| | Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. | Q34622672 |
| | Treatment Planning and Volumetric Response Assessment for Yttrium-90 Radioembolization: Semiautomated Determination of Liver Volume and Volume of Tumor Necrosis in Patients with Hepatic Malignancy | Q34681148 |
| | Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes | Q35004090 |
| | Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma | Q35085486 |
| | Hepatocellular carcinoma: Advances in diagnosis, management, and long term outcome | Q35626757 |
| | Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations. | Q36573194 |
| | Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma. | Q36673829 |
| | Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept | Q36920698 |
| | Multimodality imaging following 90Y radioembolization: a comprehensive review and pictorial essay. | Q37060054 |
| | Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection. | Q37376714 |
| | Modified RECIST (mRECIST) assessment for hepatocellular carcinoma | Q37696396 |
| | Loco-regional treatment of hepatocellular carcinoma | Q37766546 |
| | Radioembolization for hepatocellular carcinoma: a review of the evidence and treatment recommendations. | Q37771838 |
| | Need, feasibility and convenience of dosimetric treatment planning in liver selective internal radiation therapy with (90)Y microspheres: the experience of the National Tumor Institute of Milan | Q37850992 |
| | Transarterial chemoembolisation and radioembolisation for the treatment of primary liver cancer and secondary liver cancer: a review of the literature | Q38192781 |
| | In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization? | Q38984450 |
| | Variant hepatic arterial anatomy revisited: digital subtraction angiography performed in 600 patients. | Q39609899 |
| | Systematic evaluation of tumoral 99mTc-MAA uptake using SPECT and SPECT/CT in 502 patients before 90Y radioembolization | Q40255244 |
| | Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation | Q42601023 |
| | Prospective evaluation of the management of hepatocellular carcinoma in the elderly. | Q43495073 |
| | Is selective internal radioembolization safe and effective for patients with inoperable hepatocellular carcinoma and venous thrombosis? | Q44126350 |
| | Yttrium 90 resin microspheres for the treatment of unresectable colorectal hepatic metastases after failure of multiple chemotherapy regimens: preliminary results | Q44426543 |
| | Patient Selection and Activity Planning Guide for Selective Internal Radiotherapy With Yttrium-90 Resin Microspheres | Q44692003 |
| | Prognostic utility of 90Y radioembolization dosimetry based on fusion 99mTc-macroaggregated albumin-99mTc-sulfur colloid SPECT. | Q45997151 |
| | Biliary sequelae following radioembolization with Yttrium-90 microspheres | Q47746491 |
| | Liver disease induced by radioembolization of liver tumors: description and possible risk factors | Q47925759 |
| | Fibrosis, portal hypertension, and hepatic volume changes induced by intra-arterial radiotherapy with 90yttrium microspheres | Q47953062 |
| | A comparison of survival in patients with hepatocellular carcinoma and portal vein invasion treated by radioembolization or sorafenib. | Q48230943 |
| | Management and prevention of adverse effects related to treatment of liver tumours with 90Y microspheres | Q50163011 |
| | Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. | Q50535030 |
| | Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. | Q51204089 |
| | Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. | Q51642133 |
| | MDCT necrosis quantification in the assessment of hepatocellular carcinoma response to yttrium 90 radioembolization therapy: comparison of two-dimensional and volumetric techniques. | Q53193242 |
| | Incidence of radiation pneumonitis after hepatic intra-arterial radiotherapy with yttrium-90 microspheres assuming uniform lung distribution. | Q53391789 |
| | Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC. | Q53525194 |
| | Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results. | Q53671257 |
| | Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis | Q56970979 |
| | The intermediate hepatocellular carcinoma stage: Should treatment be expanded? | Q56988249 |
| | Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: A phase 2 study | Q57763422 |
| | Response to radioembolization with yttrium-90 resin microspheres may allow surgical treatment with curative intent and prolonged survival in previously unresectable hepatocellular carcinoma | Q58283601 |
| | Radiation Lobectomy: Preliminary Findings of Hepatic Volumetric Response to Lobar Yttrium-90 Radioembolization | Q63198749 |
| | Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres | Q63198750 |
| | Radiation pneumonitis after selective internal radiation treatment with intraarterial 90Yttrium-microspheres for inoperable hepatic tumors | Q71821807 |
| | Treatment of inoperable cancer of the liver by intra-arterial radioactive isotopes and chemotherapy | Q72218534 |
| | Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer | Q73323825 |
| | TREATMENT OF EXPERIMENTAL TUMORS; UTILIZATION OF RADIOACTIVE MICROSPHERES | Q76845800 |
| | New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy | Q82877410 |
| | A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization | Q84121312 |
| | Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q84424049 |
| | Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival | Q84634948 |
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatocellular carcinoma | Q1148337 |
| P304 | page(s) | 25-9 | |
| P577 | publication date | 2016-01-01 | |
| P1433 | published in | Journal of hepatocellular carcinoma | Q27727369 |
| P1476 | title | Transarterial radioembolization for hepatocellular carcinoma: a review | |
| P478 | volume | 3 | |